Finerenone in Persons with Chronic Kidney Disease without Diabetes

A study published in the New England Journal of Medicine examined the efficacy of finerenone in patients with chronic kidney disease who do not have diabetes. Finerenone is a mineralocorticoid receptor antagonist that was tested as a potential treatment to slow the progression of chronic kidney disease. The research focused on the safety and efficacy of this medication in this specific patient population. The study was published in August 2026 in volume 395 of the journal. The results contribute to understanding treatment options for chronic kidney disease in patients without diabetes mellitus. Finerenone represents a potential therapeutic approach to improve outcomes in this patient group.